Thalidomide + Dexamethasone Versus DOXIL (Doxorubicin HCl Liposome Injection) + Thalidomide + Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

This study is ongoing, but not recruiting participants.

Study NCT00097981 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

First Received: December 1, 2004 Last Updated: September 25, 2009 History of Changes

Study Type:	Interventional
Study Design:	Randomized, Open Label, Parallel Assignment
Conditions:	Cancer Multiple Myeloma
Interventions:	Drug: Thalidomide and dexamethasone Drug: Thalidomide and dexamethasone plus DOXIL

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Thalidomide + Dexamethasone	No text entered.
DOXIL + Thalidomide + Dexamethasone	No text entered.

Baseline Measures

	Thalidomide + Dexamethasone	DOXIL + Thalidomide + Dexamethasone	Total
Number of Participants [units: participants]	113	112	225
Age [units: years] Mean ± Standard Deviation	60 ± 10	61 ± 11	60 ± 11
Gender [units: participants]
Female	51	44	95
Male	62	68	130

Outcome Measures

Show All Outcome Measures

1. Primary:

Complete Response Rate Defined as the Number of Participants Who Achieve a Complete Response [ Cycle 2 until 28 days following completion of treatment ]

Show Outcome Measure 1

2. Secondary:

Overall Response [ Cycle 2 until 28 days following completion of treatment ]

Show Outcome Measure 2

3. Secondary:

Time to 1st Response [ Cycle 2 until 28 days following completion of treatment ]

Show Outcome Measure 3

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Medical Director
Organization: Centocor Ortho Biotech Services, L.L.C.
e-mail: clowery1@its.jnj.com

No publications provided

Responsible Party:	Ortho Biotech Products, L.P. ( Vice President Medical Affairs Oncology/Nephrology )
Study ID Numbers:	CR004579
Study First Received:	December 1, 2004
Results First Received:	October 2, 2008
Last Updated:	September 25, 2009
ClinicalTrials.gov Identifier:	NCT00097981 History of Changes
Health Authority:	United States: Food and Drug Administration